Most recently, the inhibition of IL-1β by using a monoclonal antibody in diabetic db/db mice with progressive kidney disease was demonstrated to reduce the expression of renal damage markers and to attenuate GFR decline [38]. This evidence concerns the gene IL1B and kidney disorder.